Drug Repurposing in Medulloblastoma: Challenges and Recommendations.
Hussein HammoudZahraa SakerHayat HaratiYoussef FaresHisham F BahmadSanaa NabhaPublished in: Current treatment options in oncology (2020)
Medulloblastoma is the most frequently diagnosed primary malignant brain tumor among children. Currently available therapeutic strategies are based on surgical resection, chemotherapy, and/or radiotherapy. However, majority of patients quickly develop therapeutic resistance and are often left with long-term therapy-related side effects and sequelae. Therefore, there remains a dire need to develop more effective therapeutics to overcome the acquired resistance to currently available therapies. Unfortunately, the process of developing novel anti-neoplastic drugs from bench to bedside is highly time-consuming and very expensive. A wide range of drugs that are already in clinical use for treating non-cancerous diseases might commonly target tumor-associated signaling pathways as well and hence be of interest in treating different cancers. This is referred to as drug repurposing or repositioning. In medulloblastoma, drug repurposing has recently gained a remarkable interest as an alternative therapy to overcome therapy resistance, wherein existing non-tumor drugs are being tested for their potential anti-neoplastic effects outside the scope of their original use.
Keyphrases
- end stage renal disease
- drug induced
- chronic kidney disease
- signaling pathway
- early stage
- newly diagnosed
- locally advanced
- ejection fraction
- squamous cell carcinoma
- radiation therapy
- adverse drug
- risk assessment
- clinical practice
- radiation induced
- mesenchymal stem cells
- epithelial mesenchymal transition
- pi k akt
- replacement therapy